Cargando…
Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
BACKGROUND AND OBJECTIVES: Dimethyl fumarate (DMF), an oral disease-modifying therapy with an established benefit and well-described safety profile, is among the most commonly used therapies for relapsing forms of multiple sclerosis. As of 31 December 2021, >560,000 patients have been treated wit...
Autores principales: | Lyons, Jennifer, Hughes, Richard, McCarthy, Kerry, Everage, Nicholas, Kapadia, Shivani, Miller, Catherine, Singhal, Priya, Smirnakis, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661630/ https://www.ncbi.nlm.nih.gov/pubmed/36387034 http://dx.doi.org/10.1177/20552173221132469 |
Ejemplares similares
-
CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
Publicado: (2023) -
Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate
por: Dammeier, Nele, et al.
Publicado: (2015) -
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions
por: Vola, Elena Augusta, et al.
Publicado: (2021) -
Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis
por: Hoepner, Robert, et al.
Publicado: (2015) -
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)